Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hydroxychloroquine pre-exposure prophylaxis for COVID-19 in healthcare workers.
Revollo B, Tebe C, Peñafiel J, Blanco I, Perez-Alvarez N, Lopez R, Rodriguez L, Ferrer J, Ricart P, Moret E, Tural C, Carreres A, Matllo J, Videla S, Clotet B, Llibre JM. Revollo B, et al. Among authors: perez alvarez n. J Antimicrob Chemother. 2021 Feb 11;76(3):827-829. doi: 10.1093/jac/dkaa477. J Antimicrob Chemother. 2021. PMID: 33219675 Free PMC article. No abstract available.
Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients.
Bonjoch A, Paredes R, Domingo P, Cervantes M, Pedrol E, Ribera E, Force L, Llibre JM, Vilaró J, Dalmau D, Cucurull J, Mascaró J, Masabeu A, Pérez-Alvarez N, Puig J, Cinquegrana D, Clotet B. Bonjoch A, et al. AIDS Res Hum Retroviruses. 2006 Apr;22(4):321-9. doi: 10.1089/aid.2006.22.321. AIDS Res Hum Retroviruses. 2006. PMID: 16623634
Reconstructive treatment for antiretroviral-associated facial lipoatrophy: a prospective study comparing autologous fat and synthetic substances.
Negredo E, Higueras C, Adell X, Martinez JC, Martinez E, Puig J, Fumaz CR, Muñoz-Moreno JA, Perez-Alvarez N, Videla S, Estany C, Cinquegrana D, Gonzalez-Mestre V, Clotet B. Negredo E, et al. AIDS Patient Care STDS. 2006 Dec;20(12):829-37. doi: 10.1089/apc.2006.20.829. AIDS Patient Care STDS. 2006. PMID: 17192148
Hill A, Moyle G. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials. HIV Med 2007; 8: 259-264. Methodological accuracy in cross-trial comparisons of antiretroviral regimens in multitreated patients.
Llibre JM, Pérez-Alvarez N. Llibre JM, et al. HIV Med. 2007 Nov;8(8):568-70; author reply 571-2. doi: 10.1111/j.1468-1293.2007.00503.x. HIV Med. 2007. PMID: 17944691 Free article. No abstract available.
Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.
Llibre JM, Bonjoch A, Iribarren J, Galindo MJ, Negredo E, Domingo P, Pérez-Alvarez N, Martinez-Picado J, Schapiro J, Clotet B; HIV Conference Call Study Group. Llibre JM, et al. HIV Med. 2008 Aug;9(7):508-13. doi: 10.1111/j.1468-1293.2008.00581.x. Epub 2008 May 15. HIV Med. 2008. PMID: 18484978 Free article.
Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients.
Moltó J, Santos JR, Pérez-Alvarez N, Cedeño S, Miranda C, Khoo S, Else L, Llibre JM, Valle M, Clotet B. Moltó J, et al. Antimicrob Agents Chemother. 2008 Nov;52(11):3928-32. doi: 10.1128/AAC.00520-08. Epub 2008 Aug 25. Antimicrob Agents Chemother. 2008. PMID: 18725446 Free PMC article.
87 results